Einführung
Diese Seite bietet eine umfassende Analyse des bekannten Insiderhandels von Nicole Vitullo. Insider sind leitende Angestellte, Direktoren oder bedeutende Investoren in einem Unternehmen. Es ist für Insider illegal, auf der Grundlage bestimmter, nicht öffentlicher Informationen mit ihren Unternehmen zu handeln. Das bedeutet nicht, dass es für sie illegal ist, irgendwelche Geschäfte in ihren eigenen Unternehmen zu tätigen. Sie müssen jedoch alle Geschäfte der SEC über ein Formular 4 melden. Trotz dieser Einschränkungen deuten akademische Untersuchungen darauf hin, dass Insider im Allgemeinen dazu neigen, den Markt in ihren eigenen Unternehmen zu übertreffen.
Durchschnittliche Handelsrentabilität
Die durchschnittliche Handelsrentabilität ist die durchschnittliche Rendite aller offenen Marktkäufe, die der Insider in den letzten drei Jahren getätigt hat. Um dies zu berechnen, untersuchen wir jeden ungeplanten Kauf, den der Insider auf dem offenen Markt getätigt hat, mit Ausnahme aller Geschäfte, die als Teil eines 10b5-1-Handelsplans gekennzeichnet waren. Anschließend berechnen wir die durchschnittliche Performance dieser Geschäfte über 3, 6 und 12 Monate, wobei wir für jeden dieser Zeiträume den Durchschnitt bilden, um eine endgültige Performance-Kennzahl für jedes Geschäft zu erhalten. Schließlich berechnen wir den Durchschnitt aller Performance-Metriken, um eine Performance-Metrik für den Insider zu ermitteln. Diese Liste enthält nur Insider, die in den letzten zwei Jahren mindestens drei Geschäfte getätigt haben.
Wenn die Handelsrentabilität dieses Insiders "N/A" ist, hat er entweder in den letzten drei Jahren keine Käufe auf dem freien Markt getätigt, oder die von ihm getätigten Geschäfte sind zu kurz her, um eine zuverlässige Performance-Kennzahl zu berechnen.
Aktualisierungshäufigkeit: Täglich
Unternehmen mit gemeldeten Insiderpositionen
Aus den SEC-Filings geht hervor, dass Nicole Vitullo Beteiligungen an den folgenden Unternehmen gemeldet oder mit ihnen gehandelt hat:
So interpretieren Sie die Diagramme
Die folgenden Diagramme zeigen die Wertentwicklung von Wertpapieren nach jedem offenen, nicht geplanten Handel von Nicole Vitullo. Nicht geplante Geschäfte sind Geschäfte, die nicht im Rahmen eines 10b5-1-Handelsplans getätigt wurden. Die Aktienperformance wird als kumulative prozentuale Veränderung des Aktienkurses dargestellt. Wenn beispielsweise am 1. Januar 2019 ein Insiderhandel getätigt wurde, zeigt das Diagramm die tägliche prozentuale Veränderung des Wertpapiers bis zum heutigen Tag. Wenn der Aktienkurs in dieser Zeit von $10 auf $15 gestiegen ist, beträgt die kumulative prozentuale Veränderung des Aktienkurses 50 %. Eine Kursveränderung von $10 auf $20 würde 100% betragen und eine Kursveränderung von $10 auf $5 wäre -50%.
Letztendlich versuchen wir festzustellen, wie eng die Geschäfte des Insiders mit den (positiven oder negativen) Überschussrenditen des Aktienkurses korrelieren, um zu sehen, ob der Insider seine Geschäfte zeitlich so abstimmt, dass er von Insiderinformationen profitiert. Stellen Sie sich die Situation vor, dass ein Insider dies tun würde. In dieser Situation würden wir entweder (a) positive Renditen nach Käufen oder (b) negative Renditen nach Verkäufen erwarten. Im Falle von (a) würde das KAUF-Diagramm eine Reihe von aufwärts gerichteten Kurven zeigen, die auf positive Renditen nach jeder Kauftransaktion hinweisen. Im Falle von (b) würde das VERKAUFS-Diagramm eine Reihe von abwärts gerichteten Kurven zeigen, die auf negative Renditen nach jeder Verkaufstransaktion hinweisen.
Dies allein reicht jedoch nicht aus, um Schlussfolgerungen zu ziehen. Wenn sich der Aktienkurs des Unternehmens beispielsweise über viele Jahre hinweg in einem nicht-zyklischen Aufwärtstrend befand, dann würden wir erwarten, dass alle Nach-Kauf-Kurven aufwärts gerichtet sind. Ebenso würden nicht-zyklische Rückgänge über viele Jahre hinweg zu abwärts geneigten Nachhandelsdiagrammen führen. Keines dieser Diagramme würde auf Insiderhandel hindeuten.
Der stärkste Indikator wäre eine Situation, in der der Aktienkurs extrem zyklisch war und es sowohl positive Signale im KAUF-Chart als auch negative im VERKAUF-Chart gab. Diese Situation würde stark auf einen Insider hindeuten, der das Timing von Geschäften zu seinem finanziellen Vorteil nutzt.
Insiderkäufe ADYX / Adynxx, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe ADYX / Adynxx, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe ALDX / Aldeyra Therapeutics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe ALDX / Aldeyra Therapeutics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe ATRA / Atara Biotherapeutics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe ATRA / Atara Biotherapeutics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe ATYR / aTyr Pharma, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe ATYR / aTyr Pharma, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe BNGO / Bionano Genomics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-08-23 | BNGO | Domain Partners VIII, L.P. | 15.000 | 6,1250 | 429 | 214,3750 | 91.875 | 35 | 82.5 | -56.565 | -61,57 |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe BNGO / Bionano Genomics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe ESPR / Esperion Therapeutics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-10-21 | ESPR | DOMAIN PARTERS VII L P | 500.000 | 20,0000 | 500.000 | 20,0000 | 10.000.000 | 210 | 115.3000 | 47.650.000 | 476,50 |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe ESPR / Esperion Therapeutics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe GKOS / Glaukos Corporation - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe GKOS / Glaukos Corporation - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe SNDX / Syndax Pharmaceuticals, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe SNDX / Syndax Pharmaceuticals, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe VCYT / Veracyte, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ADYX / Adynxx, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe VCYT / Veracyte, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ADYX / Adynxx, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Geschichte des Insiderhandels
Diese Tabelle zeigt die vollständige Liste der von Nicole Vitullo getätigten Insidergeschäfte, die der Securities Exchange Commission (SEC) gemeldet wurden.
| Datum der Einreichung | Tran Datum | Form | Ticker | Wertpapier | Code | Aktien | Verbleibende Aktien | Prozent Änderung |
Aktie Preis |
Tran Wert |
Verbleibender Wert |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-16 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 5.150 | 36.918 | 16,21 | ||||
| 2022-05-27 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
| 2022-02-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 12.375 | 12.375 | |||||
| 2022-02-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
A - Award | 2.750 | 6.442 | 74,49 | ||||
| 2021-05-28 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 12.376 | 31.768 | 63,82 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 2.717 | 3.692 | 278,67 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -11.612 | 0 | -100,00 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -6.192 | 0 | -100,00 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -4.250 | 0 | -100,00 | 15,87 | -67.448 | ||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 6.192 | 6.192 | |||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -619.221 | 0 | -100,00 | ||||
| 2021-01-20 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 16.500 | 16.500 | |||||
| 2020-11-06 |
|
4/A | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 150.000 | 150.000 | |||||
| 2020-05-29 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 6.106 | 19.392 | 45,96 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -42.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -30.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -30.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -30.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -20.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -20.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -50.000 | 0 | -100,00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -25.159 | 0 | -100,00 | 6,30 | -158.502 | ||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -3.393.382 | 0 | -100,00 | 6,30 | -21.378.307 | ||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -36.431 | 0 | -100,00 | 6,30 | -229.515 | ||
| 2020-01-10 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 100.000 | 100.000 | |||||
| 2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Warrants to Purchase Common Stock |
P - Purchase | 187.500 | 187.500 | 4,00 | 750.000 | 750.000 | ||
| 2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 250.000 | 813.433 | 44,37 | 4,00 | 1.000.000 | 3.253.732 | |
| 2019-05-31 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 4.967 | 13.286 | 59,71 | ||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 1.356 | 8.319 | 19,47 | ||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -17.790 | 0 | -100,00 | ||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -1.700 | 0 | -100,00 | 45,25 | -76.925 | ||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -13.629 | 1.700 | -88,91 | 44,66 | -608.671 | 75.922 | |
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 17.790 | 17.790 | |||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -1.101.080 | 0 | -100,00 | ||||
| 2019-02-28 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 35.000 | 35.000 | |||||
| 2019-01-25 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 42.000 | 42.000 | |||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Warrants to Purchase Common Stock |
P - Purchase | 15.000 | 15.000 | |||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -6.810.098 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -3.682.919 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -6.396.105 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -5.426.808 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -2.986.762 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
P - Purchase | 15.000 | 943.878 | 1,61 | 6,12 | 91.875 | 5.781.253 | |
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 337.694 | 929.878 | 57,03 | 4,59 | 1.550.015 | 4.268.140 | |
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 591.184 | 591.184 | |||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -50.532 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -27.328 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -47.460 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -40.268 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -22.161 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 2.505 | 6.891 | 57,11 | 4,59 | 11.498 | 31.630 | |
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 4.386 | 4.386 | |||||
| 2018-08-27 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 1.648.359 | 5.634.329 | 41,35 | 1,82 | 3.000.013 | 10.254.479 | |
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-06-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 3.846 | 6.963 | 123,39 | ||||
| 2018-06-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -21.471 | 0 | -100,00 | ||||
| 2018-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 5.000 | 36.431 | 15,91 | ||||
| 2018-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -25.000 | 0 | -100,00 | ||||
| 2018-05-25 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 10.100 | 10.100 | |||||
| 2018-02-13 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 645 | 3.177 | 25,47 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -8.500 | 0 | -100,00 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -11.674 | 15.329 | -43,23 | 71,79 | -838.076 | 1.100.469 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
M - Exercise | -1.193 | 0 | -100,00 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
M - Exercise | -70.042 | 0 | -100,00 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
F - Taxes | -117 | 27.003 | -0,43 | 71,82 | -8.403 | 1.939.355 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
M - Exercise | 1.193 | 27.120 | 4,60 | 6,99 | 8.339 | 189.569 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
F - Taxes | -6.814 | 1.101.080 | -0,62 | 71,82 | -489.381 | 79.079.566 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
M - Exercise | 70.042 | 1.107.894 | 6,75 | 6,99 | 489.594 | 7.744.179 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 8.500 | 8.500 | |||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -850.000 | 1.037.852 | -45,02 | ||||
| 2018-01-24 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 2.250 | 46.450 | 5,09 | ||||
| 2018-01-24 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -2.250 | 3.900 | -36,59 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -368 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 282 | 25.730 | 1,11 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 12.444 | 25.448 | 95,69 | 3,19 | 39.696 | 81.179 | |
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -49.632 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 37.890 | 3.469.029 | 1,10 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.678.432 | 3.431.139 | 95,76 | 3,19 | 5.354.198 | 10.945.333 | |
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -988.285 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -47.963 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -15.731 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20.150 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20.150 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -1.857.036 | 0 | -100,00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -7.333 | 0 | -100,00 | ||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 2.472 | 2.472 | |||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -32.560 | 0 | -100,00 | ||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -9.326 | 25.927 | -26,45 | 53,85 | -502.205 | 1.396.169 | |
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 3.291 | 32.560 | 11,24 | ||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -329.083 | 1.887.852 | -14,84 | ||||
| 2017-12-08 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 35.000 | 35.000 | |||||
| 2017-09-11 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 1.650 | 44.200 | 3,88 | ||||
| 2017-09-11 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -1.650 | 6.150 | -21,15 | ||||
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -20.706 | 0 | -100,00 | ||||
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -2.790.539 | 0 | -100,00 | ||||
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
F - Taxes | -12.726 | 25.159 | -33,59 | 5,06 | -64.394 | 127.305 | |
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20.706 | 37.885 | 120,53 | 3,11 | 64.447 | 117.917 | |
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1.714.954 | 3.393.382 | -33,57 | 5,06 | -8.677.667 | 17.170.513 | |
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2.790.539 | 5.108.336 | 120,40 | 3,11 | 8.685.553 | 15.899.696 | |
| 2017-04-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 14.000 | 14.000 | |||||
| 2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 49.632 | 49.632 | 100,00 | 4.963.200 | 4.963.200 | ||
| 2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 368 | 368 | 100,00 | 36.800 | 36.800 | ||
| 2017-01-19 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 10.500 | 10.500 | |||||
| 2017-01-19 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
A - Award | 4.500 | 7.800 | 136,36 | ||||
| 2017-01-19 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 17.695 | 0 | -100,00 | ||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1.071 | 0 | -100,00 | ||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1.996 | 0 | -100,00 | ||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -38.094 | 0 | -100,00 | 28,35 | -1.079.965 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -3.553.322 | 0 | -100,00 | 28,35 | -100.736.679 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -47.613 | 0 | -100,00 | 28,35 | -1.349.829 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -1.657 | 0 | -100,00 | 28,35 | -46.976 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -285.679 | 0 | -100,00 | 28,35 | -8.099.000 | ||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -14.271 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -20.583 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -11.083 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 49.570 | 49.570 | |||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series E Preferred Stock |
C - Conversion | -482.326 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -597.207 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -836.722 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -1.206.836 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -649.835 | 0 | -100,00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 3.985.970 | 3.985.970 | |||||
| 2016-09-13 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
J - Other | -1.943.109 | 0 | -100,00 | ||||
| 2016-08-05 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 7.700 | 7.700 | |||||
| 2016-08-05 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
A - Award | 3.300 | 3.300 | |||||
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -129 | 3.039 | -4,07 | 8,15 | -1.051 | 24.768 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -32 | 3.168 | -1,00 | 8,71 | -279 | 27.593 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -84 | 3.200 | -2,56 | 8,82 | -741 | 28.224 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -81.094 | 1.943.109 | -4,01 | 8,15 | -660.916 | 15.836.338 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19.718 | 2.024.203 | -0,96 | 8,71 | -171.744 | 17.630.808 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -52.216 | 2.043.921 | -2,49 | 8,82 | -460.545 | 18.027.383 | |
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
D - Sale to Issuer | -14.000 | 0 | -100,00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
D - Sale to Issuer | -14.000 | 0 | -100,00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
D - Sale to Issuer | -28.000 | 0 | -100,00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
D - Sale to Issuer | -85.777 | 0 | -100,00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
D - Sale to Issuer | -32.091 | 0 | -100,00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
D - Sale to Issuer | -44.495 | 0 | -100,00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
D - Sale to Issuer | -5.867 | 0 | -100,00 | 30,25 | -177.477 | ||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
D - Sale to Issuer | -16.733 | 0 | -100,00 | 30,25 | -506.173 | ||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
D - Sale to Issuer | -2.378.924 | 0 | -100,00 | 30,25 | -71.962.451 | ||
| 2016-06-13 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8.000 | 8.000 | |||||
| 2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -5.880 | 10.328 | -36,28 | 4,70 | -27.636 | 48.542 | |
| 2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -344.120 | 606.283 | -36,21 | 4,70 | -1.617.364 | 2.849.530 | |
| 2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -149.765 | 2.096.137 | -6,67 | 6,96 | -1.042.364 | 14.589.114 | |
| 2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -235 | 3.284 | -6,68 | 6,96 | -1.636 | 22.857 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -61 | 16.208 | -0,37 | 5,02 | -306 | 81.364 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -21 | 16.269 | -0,13 | 5,20 | -109 | 84.599 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -3.603 | 950.403 | -0,38 | 5,02 | -18.087 | 4.771.023 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -1.492 | 954.006 | -0,16 | 5,20 | -7.758 | 4.960.831 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -76 | 16.290 | -0,46 | 5,29 | -402 | 86.174 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -632 | 16.366 | -3,72 | 5,36 | -3.388 | 87.722 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4.424 | 955.498 | -0,46 | 5,29 | -23.403 | 5.054.584 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -37.054 | 959.922 | -3,72 | 5,36 | -198.609 | 5.145.182 | |
| 2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -75 | 16.998 | -0,44 | 5,22 | -392 | 88.730 | |
| 2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4.348 | 996.976 | -0,43 | 5,22 | -22.697 | 5.204.215 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -251 | 17.073 | -1,45 | 5,35 | -1.343 | 91.341 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -475 | 17.324 | -2,67 | 5,26 | -2.498 | 91.124 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -148 | 17.799 | -0,82 | 5,22 | -773 | 92.911 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -14.554 | 1.001.324 | -1,43 | 5,35 | -77.864 | 5.357.083 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -27.781 | 1.015.878 | -2,66 | 5,26 | -146.128 | 5.343.518 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -8.669 | 1.043.659 | -0,82 | 5,22 | -45.252 | 5.447.900 | |
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -360.640 | 0 | -100,00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -400.422 | 0 | -100,00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 761.062 | 761.062 | |||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -2.674 | 0 | -100,00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -2.967 | 0 | -100,00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 5.641 | 5.641 | |||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -13.925 | 0 | -100,00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 13.925 | 13.925 | |||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -444.460 | 0 | -100,00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -1.299.394 | 0 | -100,00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.743.854 | 1.743.854 | |||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
| 2016-01-26 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -370 | 17.179 | -2,11 | 10,31 | -3.815 | 177.115 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -49.630 | 2.317.797 | -2,10 | 10,31 | -511.685 | 23.896.487 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -1.325 | 17.549 | -7,02 | 10,43 | -13.820 | 183.036 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -177.749 | 2.367.427 | -6,98 | 10,43 | -1.853.922 | 24.692.264 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -2.375 | 18.874 | -11,18 | 10,01 | -23.774 | 188.929 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -318.551 | 2.545.176 | -11,12 | 10,01 | -3.188.696 | 25.477.212 | |
| 2015-09-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -69 | 21.249 | -0,32 | 8,22 | -567 | 174.667 | |
| 2015-09-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -9.241 | 2.863.727 | -0,32 | 8,22 | -75.961 | 23.539.836 | |
| 2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -11.836 | 1.052.328 | -1,11 | 7,02 | -83.089 | 7.387.343 | |
| 2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -202 | 17.947 | -1,11 | 7,02 | -1.418 | 125.988 | |
| 2015-08-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 31.431 | 31.431 | |||||
| 2015-08-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -483.521 | 0 | -100,00 | ||||
| 2015-08-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -37.843 | 21.318 | -63,97 | 7,51 | -284.201 | 160.098 | |
| 2015-07-22 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 6.300 | 6.300 | |||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -286.983 | 0 | -100,00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -589.100 | 0 | -100,00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 876.083 | 876.083 | |||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -2.130 | 0 | -100,00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -4.371 | 0 | -100,00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 6.501 | 6.501 | |||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
| 2015-06-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 14.000 | 14.000 | |||||
| 2015-05-22 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 222.630 | 483.521 | 85,33 | ||||
| 2015-05-22 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1.700.000 | 2.872.968 | -37,17 | ||||
| 2015-05-15 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8.000 | 8.000 | |||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -887.073 | 0 | -100,00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -1.506.901 | 0 | -100,00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -12.143.933 | 0 | -100,00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 1.807.820 | 1.807.820 | |||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -6.581 | 0 | -100,00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -11.182 | 0 | -100,00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -90.110 | 0 | -100,00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 13.414 | 13.414 | |||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1.565 | 0 | -100,00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -1.954 | 0 | -100,00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 3.519 | 3.519 | |||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -464.756 | 0 | -100,00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -939.289 | 0 | -100,00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -798.188 | 0 | -100,00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2.202.233 | 2.245.902 | 5.043,01 | ||||
| 2015-05-06 |
|
4 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
J - Other | 36.187 | 38.094 | 1.897,59 | ||||
| 2015-05-06 |
|
4 | TBRA |
Regado Biosciences Inc
Common Stock |
P - Purchase | 277.777 | 3.553.322 | 8,48 | 10,62 | 2.949.992 | 37.736.280 | |
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -32.411 | 1.064.164 | -2,96 | 7,07 | -229.146 | 7.523.639 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -7.920 | 1.096.575 | -0,72 | 7,58 | -60.034 | 8.312.038 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -9.832 | 1.104.495 | -0,88 | 7,78 | -76.493 | 8.592.971 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -554 | 18.149 | -2,96 | 7,07 | -3.917 | 128.313 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -135 | 18.703 | -0,72 | 7,58 | -1.023 | 141.769 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -168 | 18.838 | -0,88 | 7,78 | -1.307 | 146.560 | |
| 2015-03-24 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -350.000 | 2.216.935 | -13,63 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2.827 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1.570 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102.282 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36.913 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104.247 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12.578 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1.725 | 48.025 | -3,47 | 14,00 | -24.150 | 672.350 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2.827 | 49.750 | 6,02 | 8,54 | 24.143 | 424.865 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46.923 | -2,00 | 14,00 | -13.412 | 656.922 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1.570 | 47.881 | 3,39 | 8,54 | 13.408 | 408.904 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46.311 | 46.311 | |||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165.790 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92.105 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7.252.144 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.164.305 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6.111.968 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737.422 | 0 | -100,00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70.000 | 3.091.643 | 2,32 | 14,00 | 980.000 | 43.283.002 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101.132 | 3.021.643 | -3,24 | 14,00 | -1.415.848 | 42.303.002 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165.790 | 3.122.775 | 5,61 | 8,54 | 1.415.847 | 26.668.498 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56.185 | 2.956.985 | -1,86 | 14,00 | -786.590 | 41.397.790 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92.105 | 3.013.170 | 3,15 | 8,54 | 786.577 | 25.732.472 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2.921.065 | 2.921.065 | |||||
| 2014-12-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | |||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165.790 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92.105 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7.252.144 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.164.305 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6.111.968 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737.422 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70.000 | 3.091.642 | 2,32 | 14,00 | 980.000 | 43.282.988 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101.132 | 3.021.642 | -3,24 | 14,00 | -1.415.848 | 42.302.988 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165.790 | 3.122.774 | 5,61 | 8,54 | 1.415.847 | 26.668.490 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56.185 | 2.956.984 | -1,86 | 14,00 | -786.590 | 41.397.776 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92.105 | 3.013.169 | 3,15 | 8,54 | 786.577 | 25.732.463 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2.921.064 | 2.921.064 | |||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2.827 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1.570 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102.282 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36.913 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104.247 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12.578 | 0 | -100,00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1.725 | 48.023 | -3,47 | 14,00 | -24.150 | 672.322 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2.827 | 49.748 | 6,03 | 8,54 | 24.143 | 424.848 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46.921 | -2,00 | 14,00 | -13.412 | 656.894 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1.570 | 47.879 | 3,39 | 8,54 | 13.408 | 408.887 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46.309 | 46.309 | |||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -6.250 | 0 | -100,00 | ||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | -8.575 | 0 | -100,00 | ||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -22.306 | 0 | -100,00 | ||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -3.006.132 | 0 | -100,00 | ||||
| 2014-10-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 500.000 | 2.566.935 | 24,19 | 20,00 | 10.000.000 | 51.338.700 | |
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -4.606 | 0 | -100,00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -9.443 | 0 | -100,00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 1.841 | 15.890 | 13,10 | 11,00 | 20.251 | 174.790 | |
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 14.049 | 14.049 | |||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -620.776 | 0 | -100,00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1.272.607 | 0 | -100,00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 248.159 | 2.141.542 | 13,11 | 11,00 | 2.729.749 | 23.556.962 | |
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1.893.383 | 1.893.383 | |||||
| 2014-10-01 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 6.000 | 6.000 | |||||
| 2014-09-12 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
J - Other | -300.000 | 2.763.294 | -9,79 | ||||
| 2014-09-11 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 100.995 | 260.891 | 63,16 | ||||
| 2014-09-11 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1.200.000 | 4.572.968 | -20,79 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -502 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -1.386 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -6.866 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -3.238 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -277 | 11.715 | -2,31 | 16,00 | -4.432 | 187.440 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 502 | 11.992 | 4,37 | 8,79 | 4.413 | 105.410 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 11.490 | 11.490 | |||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -67.755 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -186.828 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -925.479 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -436.485 | 0 | -100,00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -37.224 | 1.579.323 | -2,30 | 16,00 | -595.584 | 25.269.168 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 67.755 | 1.616.547 | 4,37 | 8,79 | 595.566 | 14.209.448 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 1.548.792 | 1.548.792 | |||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1.165 | 0 | -100,00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -7.043 | 0 | -100,00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -8.792 | 0 | -100,00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 17.000 | 17.000 | |||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -579.630 | 0 | -100,00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -657.192 | 0 | -100,00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -820.320 | 0 | -100,00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 419.744 | 2.476.886 | 20,40 | 8,00 | 3.357.952 | 19.815.088 | |
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 2.057.142 | 2.057.142 | |||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
| 2014-06-13 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 14.000 | 14.000 | |||||
| 2014-05-22 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8.575 | 8.575 | |||||
| 2014-05-16 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 5.000 | 5.000 | |||||
| 2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Convertible Promissory Note |
C - Conversion | 0 | ||||||
| 2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 21.250 | 1.973.389 | 1,09 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3.882 | 0 | -100,00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 9.208 | 9.208 | |||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60.576 | 0 | -100,00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60.576 | 0 | -100,00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -755.263 | 0 | -100,00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -486.316 | 0 | -100,00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39.063 | 1.952.139 | -1,96 | 8,00 | -312.504 | 15.617.112 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39.063 | 1.952.139 | -1,96 | 8,00 | -312.504 | 15.617.112 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60.576 | 1.991.202 | 3,14 | 5,16 | 312.572 | 10.274.602 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60.576 | 1.991.202 | 3,14 | 5,16 | 312.572 | 10.274.602 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1.909.113 | 1.909.113 | |||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -27.500 | 0 | -100,00 | 14,00 | -385.000 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -78.369 | 0 | -100,00 | 14,00 | -1.097.166 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -7.313.241 | 0 | -100,00 | 14,00 | -102.385.374 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -50.743 | 0 | -100,00 | 14,00 | -710.402 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -2.972.678 | 0 | -100,00 | 14,00 | -41.617.492 | ||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -7.430 | 0 | -100,00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -15.799 | 0 | -100,00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -10.661 | 0 | -100,00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -435.663 | 0 | -100,00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -926.321 | 0 | -100,00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -625.065 | 0 | -100,00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 33.890 | 33.890 | |||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 1.987.049 | 1.987.049 | |||||
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -1.367.020 | 0 | -100,00 | ||||
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -765.532 | 2.972.678 | -20,48 | 14,00 | -10.717.448 | 41.617.492 | |
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1.367.020 | 3.738.210 | 57,65 | 7,84 | 10.717.437 | 29.307.566 | |
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -23.317 | 0 | -100,00 | ||||
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -13.058 | 50.743 | -20,47 | 14,00 | -182.812 | 710.402 | |
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 23.317 | 63.801 | 57,60 | 7,84 | 182.805 | 500.200 | |
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 156 | 156 | |||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -156 | 0 | -100,00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -9.469 | 0 | -100,00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3.535 | 0 | -100,00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 21.041 | 21.041 | |||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -21.041 | 0 | -100,00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -1.276.243 | 0 | -100,00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -476.464 | 0 | -100,00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 13.004 | 13.004 | |||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.752.707 | 1.752.707 | |||||
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -2.230 | 34.907 | -6,00 | 6,56 | -14.629 | 228.990 |
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -1.010 | 37.137 | -2,65 | 6,01 | -6.070 | 223.193 |
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -204.315 | 3.590.931 | -5,38 | 6,56 | -1.340.306 | 23.556.507 |
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -92.445 | 3.795.246 | -2,38 | 6,01 | -555.594 | 22.809.428 |
| 2013-12-19 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 6.008 | 6.008 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -10.068 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -38.941 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -9.378 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -6.071 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 352.351 | 352.351 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -590.403 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -2.283.114 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -549.833 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -356.111 | 0 | -100,00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 54.390 | 54.390 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 3.189.058 | 3.189.058 | |||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -5.053 | 0 | -100,00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -680.972 | 0 | -100,00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -17.677 | 0 | -100,00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -2.382.322 | 0 | -100,00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 22.730 | 22.730 | |||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 3.063.294 | 3.063.294 | |||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -19.006 | 0 | -100,00 | ||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -1.114.327 | 0 | -100,00 | ||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 19.006 | 19.006 | |||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 1.114.327 | 1.114.327 | |||||
| 2013-09-24 | 3 | EVOK |
Evoke Pharma Inc
Common Stock |
5.250 | ||||||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -7.407 | 0 | -100,00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -2.899 | 0 | -100,00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -4.233 | 0 | -100,00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series E Preferred Stock |
C - Conversion | -225.913 | 0 | -100,00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -894.120 | 0 | -100,00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -270.568 | 0 | -100,00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -394.969 | 0 | -100,00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 7.407 | 14.920 | 98,59 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 2.899 | 7.513 | 62,83 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 4.233 | 4.614 | 1.111,02 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
P - Purchase | 750.000 | 2.571.117 | 41,18 | 4,00 | 3.000.000 | 10.284.468 | |
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 225.913 | 1.821.117 | 14,16 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 894.120 | 1.595.204 | 127,53 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 270.568 | 701.084 | 62,85 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 394.969 | 430.516 | 1.111,12 | ||||
| 2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
35.547 | ||||||||
| 2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
381 | ||||||||
| 2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
17.171 | ||||||||
| 2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331.873 | 1.857.036 | 21,76 | 6,03 | 1.999.999 | 11.191.242 | |
| 2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7.333 | 7.333 | 6,03 | 44.192 | 44.192 | ||
| 2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988.285 | 988.285 | 6,03 | 5.955.801 | 5.955.801 | ||
| 2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47.963 | ||||||||
| 2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1.525.163 | ||||||||
| 2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15.731 | ||||||||
| 2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331.873 | 1.897.336 | 21,20 | 6,03 | 1.999.999 | 11.434.106 | |
| 2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7.333 | 7.333 | 6,03 | 44.192 | 44.192 | ||
| 2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988.285 | 988.285 | 6,03 | 5.955.801 | 5.955.801 | ||
| 2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47.963 | ||||||||
| 2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1.565.463 | ||||||||
| 2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15.731 | ||||||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 1.193 | 1.193 | |||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -8.346 | 0 | -100,00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -30.462 | 0 | -100,00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 70.042 | 70.042 | |||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -489.320 | 0 | -100,00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1.786.012 | 0 | -100,00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4.791 | 35.253 | 15,73 | 14,00 | 67.074 | 493.542 | |
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 30.462 | 30.462 | |||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 280.923 | 2.066.935 | 15,73 | 14,00 | 3.932.922 | 28.937.090 | |
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1.786.012 | 1.786.012 | |||||
| 2013-06-25 | 3 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
21.471 | ||||||||
| 2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -114 | 38.147 | -0,30 | 5,01 | -571 | 191.116 |
| 2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -10.516 | 3.887.691 | -0,27 | 5,01 | -52.685 | 19.477.332 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -22.423 | 3.898.207 | -0,57 | 5,37 | -120.412 | 20.933.372 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -32.855 | 3.920.630 | -0,83 | 5,40 | -177.417 | 21.171.402 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -244 | 38.261 | -0,63 | 5,37 | -1.310 | 205.462 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -359 | 38.505 | -0,92 | 5,40 | -1.939 | 207.927 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -959 | 38.864 | -2,41 | 5,40 | -5.179 | 209.866 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -425 | 39.823 | -1,06 | 5,03 | -2.138 | 200.310 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -87.812 | 3.953.485 | -2,17 | 5,40 | -474.185 | 21.348.819 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -38.897 | 4.041.297 | -0,95 | 5,03 | -195.652 | 20.327.724 |
| 2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -59 | 40.248 | -0,15 | 5,00 | -295 | 201.240 |
| 2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -5.337 | 4.080.194 | -0,13 | 5,00 | -26.685 | 20.400.970 |
| 2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -159.192 | 2.581.745 | -5,81 | 64,58 | -10.280.619 | 166.729.092 | |
| 2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2.779 | 44.034 | -5,94 | 64,58 | -179.468 | 2.843.716 | |
| 2013-06-04 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 28.000 | 28.000 | |||||
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -232 | 40.307 | -0,57 | 4,50 | -1.044 | 181.382 | |
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -251 | 40.539 | -0,62 | 4,70 | -1.180 | 190.533 | |
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -21.276 | 4.085.531 | -0,52 | 4,50 | -95.742 | 18.384.890 | |
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -22.966 | 4.106.807 | -0,56 | 4,70 | -107.940 | 19.301.993 | |
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
J - Other | 85.777 | 85.777 | |||||
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
J - Other | 12.906 | 32.091 | 67,27 | ||||
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
J - Other | 17.895 | 44.495 | 67,27 | ||||
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
J - Other | 156.749 | 2.378.924 | 7,05 | ||||
| 2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23.210 | 2.371.190 | -0,97 | 6,62 | -153.650 | 15.697.278 |
| 2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -71.578 | 7.313.241 | -0,97 | 6,62 | -473.846 | 48.413.655 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.567 | 2.394.400 | -0,07 | 6,72 | -10.530 | 16.090.368 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11.386 | 2.395.967 | -0,47 | 6,71 | -76.400 | 16.076.939 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.217 | 2.407.353 | -0,50 | 6,52 | -79.655 | 15.695.942 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.832 | 7.384.819 | -0,07 | 6,72 | -32.471 | 49.625.984 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -35.114 | 7.389.651 | -0,47 | 6,71 | -235.615 | 49.584.558 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -37.676 | 7.424.765 | -0,50 | 6,52 | -245.648 | 48.409.468 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.374 | 2.419.570 | -0,18 | 5,35 | -23.401 | 12.944.700 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -893 | 40.484 | -2,16 | 5,49 | -4.903 | 222.257 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13.490 | 7.462.441 | -0,18 | 5,35 | -72.172 | 39.924.059 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.743 | 78.369 | -2,18 | 5,49 | -9.569 | 430.246 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.510 | 2.423.944 | -0,23 | 5,22 | -28.762 | 12.652.988 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7.925 | 2.429.454 | -0,33 | 5,19 | -41.131 | 12.608.866 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -92 | 41.377 | -0,22 | 5,22 | -480 | 215.988 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 41.469 | -0,32 | 5,19 | -695 | 215.224 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -182 | 80.112 | -0,23 | 5,22 | -950 | 418.185 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -261 | 80.294 | -0,32 | 5,19 | -1.355 | 416.726 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16.995 | 7.475.931 | -0,23 | 5,22 | -88.714 | 39.024.360 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24.442 | 7.492.926 | -0,33 | 5,19 | -126.854 | 38.888.286 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -8.020 | 2.437.379 | -0,33 | 5,16 | -41.383 | 12.576.876 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.636 | 2.445.399 | -0,39 | 5,28 | -50.878 | 12.911.707 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -135 | 41.603 | -0,32 | 5,16 | -697 | 214.671 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -163 | 41.738 | -0,39 | 5,28 | -861 | 220.377 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -265 | 80.555 | -0,33 | 5,16 | -1.367 | 415.664 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -318 | 80.820 | -0,39 | 5,28 | -1.679 | 426.730 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24.736 | 7.517.368 | -0,33 | 5,16 | -127.638 | 38.789.619 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -29.719 | 7.542.104 | -0,39 | 5,28 | -156.916 | 39.822.309 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.020 | 2.455.035 | -0,20 | 5,36 | -26.907 | 13.158.988 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7.733 | 2.460.055 | -0,31 | 5,40 | -41.758 | 13.284.297 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -85 | 41.901 | -0,20 | 5,36 | -456 | 224.589 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -131 | 41.986 | -0,31 | 5,40 | -707 | 226.724 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -166 | 81.138 | -0,20 | 5,36 | -890 | 434.900 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -256 | 81.304 | -0,31 | 5,40 | -1.382 | 439.042 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.480 | 7.571.823 | -0,20 | 5,36 | -82.973 | 40.584.971 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23.848 | 7.587.303 | -0,31 | 5,40 | -128.779 | 40.971.436 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6.346 | 2.467.788 | -0,26 | 5,38 | -34.141 | 13.276.699 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.118 | 2.474.134 | -0,17 | 5,34 | -21.990 | 13.211.876 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -107 | 42.117 | -0,25 | 5,38 | -576 | 226.589 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -70 | 42.224 | -0,17 | 5,34 | -374 | 225.476 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -210 | 81.560 | -0,26 | 5,38 | -1.130 | 438.793 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -136 | 81.770 | -0,17 | 5,34 | -726 | 436.652 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19.569 | 7.611.151 | -0,26 | 5,38 | -105.281 | 40.947.992 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.700 | 7.630.720 | -0,17 | 5,34 | -67.818 | 40.748.045 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.154 | 2.478.252 | -0,21 | 5,32 | -27.419 | 13.184.301 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.701 | 2.483.406 | -0,51 | 5,22 | -66.299 | 12.963.379 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42.294 | -0,21 | 5,32 | -468 | 225.004 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -215 | 42.382 | -0,50 | 5,22 | -1.122 | 221.234 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 81.906 | -0,21 | 5,32 | -910 | 435.740 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -420 | 82.077 | -0,51 | 5,22 | -2.192 | 428.442 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.892 | 7.643.420 | -0,21 | 5,32 | -84.545 | 40.662.994 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -39.168 | 7.659.312 | -0,51 | 5,22 | -204.457 | 39.981.609 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -3.839 | 2.496.107 | -0,15 | 5,06 | -19.425 | 12.630.301 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.039 | 2.499.946 | -0,16 | 5,01 | -20.235 | 12.524.729 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -65 | 42.597 | -0,15 | 5,06 | -329 | 215.541 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -69 | 42.662 | -0,16 | 5,01 | -346 | 213.737 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11.841 | 7.698.480 | -0,15 | 5,06 | -59.915 | 38.954.309 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.454 | 7.710.321 | -0,16 | 5,01 | -62.395 | 38.628.708 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -127 | 82.497 | -0,15 | 5,06 | -643 | 417.435 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 82.624 | -0,16 | 5,01 | -671 | 413.946 |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -1.651 | 46.813 | -3,41 | 24,51 | -40.466 | 1.147.387 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2.132 | 48.464 | -4,21 | 24,69 | -52.639 | 1.196.576 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -417 | 50.596 | -0,82 | 24,44 | -10.191 | 1.236.566 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -98.349 | 2.740.937 | -3,46 | 24,51 | -2.410.534 | 67.180.366 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -126.868 | 2.839.286 | -4,28 | 24,69 | -3.132.371 | 70.101.971 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -24.783 | 2.966.154 | -0,83 | 24,44 | -605.697 | 72.492.804 | |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.145 | 2.503.985 | -0,21 | 5,01 | -25.776 | 12.544.965 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7.635 | 2.509.130 | -0,30 | 5,01 | -38.251 | 12.570.741 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42.731 | -0,21 | 5,01 | -441 | 214.082 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -130 | 42.819 | -0,30 | 5,01 | -651 | 214.523 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -170 | 82.758 | -0,20 | 5,01 | -852 | 414.618 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -253 | 82.928 | -0,30 | 5,01 | -1.268 | 415.469 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.865 | 7.722.775 | -0,21 | 5,01 | -79.484 | 38.691.103 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23.548 | 7.738.640 | -0,30 | 5,01 | -117.975 | 38.770.586 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.998 | 2.516.765 | -0,08 | 5,01 | -10.010 | 12.608.993 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34 | 42.949 | -0,08 | 5,01 | -170 | 215.174 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6.160 | 7.762.188 | -0,08 | 5,01 | -30.862 | 38.888.562 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -66 | 83.181 | -0,08 | 5,01 | -331 | 416.737 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10.076 | 2.518.763 | -0,40 | 5,02 | -50.582 | 12.644.190 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2.967 | 2.528.839 | -0,12 | 5,00 | -14.835 | 12.644.195 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 42.983 | -0,40 | 5,02 | -858 | 215.775 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43.154 | -0,12 | 5,00 | -255 | 215.770 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -334 | 83.247 | -0,40 | 5,02 | -1.677 | 417.900 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -99 | 83.581 | -0,12 | 5,00 | -495 | 417.905 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -31.075 | 7.768.348 | -0,40 | 5,02 | -155.996 | 38.997.107 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.148 | 7.799.423 | -0,12 | 5,00 | -45.740 | 38.997.115 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2.951 | 2.531.806 | -0,12 | 5,01 | -14.785 | 12.684.348 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.763 | 2.534.757 | -0,23 | 5,00 | -28.815 | 12.673.785 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43.205 | -0,12 | 5,01 | -256 | 216.457 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 43.256 | -0,23 | 5,00 | -490 | 216.280 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 83.680 | -0,12 | 5,01 | -491 | 419.237 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -191 | 83.778 | -0,23 | 5,00 | -955 | 418.890 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.100 | 7.808.571 | -0,12 | 5,01 | -45.591 | 39.120.941 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -17.770 | 7.817.671 | -0,23 | 5,00 | -88.850 | 39.088.355 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.769 | 2.540.520 | -0,38 | 4,85 | -47.380 | 12.321.522 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -164 | 43.354 | -0,38 | 4,85 | -795 | 210.267 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -30.134 | 7.835.441 | -0,38 | 4,85 | -146.150 | 38.001.889 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -322 | 83.969 | -0,38 | 4,85 | -1.562 | 407.250 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -18.537 | 2.550.289 | -0,72 | 4,71 | -87.309 | 12.011.861 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11.105 | 2.568.826 | -0,43 | 5,00 | -55.525 | 12.844.130 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -314 | 43.518 | -0,72 | 4,71 | -1.479 | 204.970 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -188 | 43.832 | -0,43 | 5,00 | -940 | 219.160 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -57.165 | 7.865.575 | -0,72 | 4,71 | -269.247 | 37.046.858 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34.248 | 7.922.740 | -0,43 | 5,00 | -171.240 | 39.613.700 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -613 | 84.291 | -0,72 | 4,71 | -2.887 | 397.011 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -367 | 84.904 | -0,43 | 5,00 | -1.835 | 424.520 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.320 | 2.579.931 | -0,59 | 5,27 | -80.736 | 13.596.236 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16.660 | 2.595.251 | -0,64 | 5,40 | -89.964 | 14.014.355 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -260 | 44.020 | -0,59 | 5,27 | -1.370 | 231.985 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -282 | 44.280 | -0,63 | 5,40 | -1.523 | 239.112 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -47.247 | 7.956.988 | -0,59 | 5,27 | -248.992 | 41.933.327 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51.377 | 8.004.235 | -0,64 | 5,40 | -277.436 | 43.222.869 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -507 | 85.271 | -0,59 | 5,27 | -2.672 | 449.378 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -551 | 85.778 | -0,64 | 5,40 | -2.975 | 463.201 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13.790 | 2.611.911 | -0,53 | 5,38 | -74.190 | 14.052.081 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -36.324 | 2.625.701 | -1,36 | 5,45 | -197.966 | 14.310.070 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -234 | 44.562 | -0,52 | 5,38 | -1.259 | 239.744 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -616 | 44.796 | -1,36 | 5,45 | -3.357 | 244.138 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -456 | 86.329 | -0,53 | 5,38 | -2.453 | 464.450 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.201 | 86.785 | -1,36 | 5,45 | -6.545 | 472.978 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -42.525 | 8.055.612 | -0,53 | 5,38 | -228.784 | 43.339.193 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -111.022 | 8.098.137 | -1,35 | 5,45 | -605.070 | 44.134.847 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -25.354 | 2.662.025 | -0,94 | 5,11 | -129.559 | 13.602.948 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -14.966 | 2.687.379 | -0,55 | 5,02 | -75.129 | 13.490.643 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -430 | 45.412 | -0,94 | 5,11 | -2.197 | 232.055 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -254 | 45.842 | -0,55 | 5,02 | -1.275 | 230.127 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -839 | 87.986 | -0,94 | 5,11 | -4.287 | 449.608 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -495 | 88.825 | -0,55 | 5,02 | -2.485 | 445.902 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -78.188 | 8.210.159 | -0,94 | 5,11 | -399.541 | 41.953.912 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -46.153 | 8.288.347 | -0,55 | 5,02 | -231.688 | 41.607.502 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19.080 | 2.702.345 | -0,70 | 5,19 | -99.025 | 14.025.171 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.615 | 2.721.425 | -0,46 | 5,35 | -67.490 | 14.559.624 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -324 | 46.096 | -0,70 | 5,19 | -1.682 | 239.238 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -214 | 46.420 | -0,46 | 5,35 | -1.145 | 248.347 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -58.838 | 8.334.500 | -0,70 | 5,19 | -305.369 | 43.256.055 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -38.903 | 8.393.338 | -0,46 | 5,35 | -208.131 | 44.904.358 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -631 | 89.320 | -0,70 | 5,19 | -3.275 | 463.571 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -418 | 89.951 | -0,46 | 5,35 | -2.236 | 481.238 |
| 2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 66.462 | 159.896 | 71,13 | ||||
| 2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1.000.000 | 5.772.968 | -14,76 | ||||
| 2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
2.222.175 | ||||||||
| 2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
16.733 | ||||||||
| 2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
5.868 | ||||||||
| 2012-12-20 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 20.000 | 20.000 | |||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -16.529 | 0 | -100,00 | ||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -2.227.596 | 0 | -100,00 | ||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 5.777 | 22.306 | 34,95 | 9,00 | 51.993 | 200.754 | |
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 16.529 | 16.529 | |||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 778.536 | 3.006.132 | 34,95 | 9,00 | 7.006.824 | 27.055.188 | |
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 2.227.596 | 2.227.596 | |||||
| 2012-07-18 | 3 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
6.250 | ||||||||
| 2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 93.434 | 93.434 | |||||
| 2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1.200.000 | 6.772.968 | -15,05 | ||||
| 2004-05-12 | 3 | NUVA |
NUVASIVE INC
Common Stock |
8.000 |
